AMEX:MTNB

Stock Analysis Report

Executive Summary

Matinas BioPharma Holdings, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of various product candidates.

Snowflake

Fundamentals

Flawless balance sheet with limited growth.

Share Price & News

How has Matinas BioPharma Holdings's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

2.3%

MTNB

1.7%

US Biotechs

0.5%

US Market


1 Year Return

-17.0%

MTNB

-7.2%

US Biotechs

6.8%

US Market

Return vs Industry: MTNB underperformed the US Biotechs industry which returned -7.2% over the past year.

Return vs Market: MTNB underperformed the US Market which returned 6.8% over the past year.


Shareholder returns

MTNBIndustryMarket
7 Day2.3%1.7%0.5%
30 Day10.7%-3.4%-0.8%
90 Day2.2%-1.3%-0.9%
1 Year-17.0%-17.0%-6.3%-7.2%9.2%6.8%
3 Year-57.5%-57.5%14.8%10.9%45.6%36.2%
5 Year16.2%16.2%-2.3%-7.0%63.2%45.4%

Price Volatility Vs. Market

How volatile is Matinas BioPharma Holdings's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Matinas BioPharma Holdings undervalued compared to its fair value and its price relative to the market?

3.26x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: MTNB ($0.7) is trading above our estimate of fair value ($0.08)

Significantly Below Fair Value: MTNB is trading above our estimate of fair value.


Price To Earnings Ratio

PE vs Industry: MTNB is unprofitable, so we can't compare its PE Ratio to the Biotechs industry average.

PE vs Market: MTNB is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate MTNB's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: MTNB is overvalued based on its PB Ratio (3.3x) compared to the US Biotechs industry average (2.6x).


Next Steps

Future Growth

How is Matinas BioPharma Holdings forecast to perform in the next 1 to 3 years based on estimates from 4 analysts?

6.9%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: MTNB is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: MTNB is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: MTNB is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: MTNB's revenue (85% per year) is forecast to grow faster than the US market (7.2% per year).

High Growth Revenue: MTNB's revenue (85% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if MTNB's Return on Equity is forecast to be high in 3 years time


Next Steps

Past Performance

How has Matinas BioPharma Holdings performed over the past 5 years?

-16.0%

Historical annual earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

Earnings Trend: MTNB is unprofitable, and losses have increased over the past 5 years at a rate of -16% per year.

Accelerating Growth: Unable to compare MTNB's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: MTNB is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (78.4%).


Return on Equity

High ROE: MTNB has a negative Return on Equity (-34.53%), as it is currently unprofitable.


Return on Assets

ROA vs Industry: MTNB is currently unprofitable, so its Return on Assets is negative.


Return on Capital Employed

ROCE Improving: MTNB is currently unprofitable, so its Return on Capital Employed is negative.


Next Steps

Financial Health

How is Matinas BioPharma Holdings's financial position?


Financial Position Analysis

Short Term Liabilities: MTNB's short term assets ($37.4M) exceeds its short term liabilities ($3.5M)

Long Term Liabilities: MTNB's short term assets (37.4M) exceeds its long term liabilities (4.3M)


Debt to Equity History and Analysis

Debt Level: MTNB is debt free.

Reducing Debt: MTNB had no debt 5 years ago.


Balance Sheet

Inventory Level: MTNB has a low level of unsold assets or inventory.

Debt Coverage by Assets: MTNB's debt is not covered by short term assets (assets are -4.2137446902432E+16x debt).


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: MTNB has sufficient cash runway for more than 3 years based on its current free cash flow.

Forecast Cash Runway: MTNB has sufficient cash runway for 1.297812 years if free cash flow continues to reduce at historical rates of -19.1% each year.


Next Steps

Dividend

What is Matinas BioPharma Holdings's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

companyn/amarketbottom25%1.4%markettop25%3.7%industryaverage2.0%forecastin3Yearsn/a

Current dividend yield vs market & industry


Stability and Growth of Payments

Notable Dividend: Unable to evaluate MTNB's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate MTNB's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.

Stable Dividend: Insufficient data to determine if MTNB's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if MTNB's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of MTNB's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

What is the CEO of Matinas BioPharma Holdings's salary, the management and board of directors tenure and is there insider trading?

1.0yrs

Average management tenure


CEO

Jerry Jabbour (45yo)

1.6yrs

Tenure

US$1,254,727

Compensation

Mr. Jerome D. Jabbour, also known as Jerry, J.D., Co Founded Matinas BioPharma Holdings, Inc. and has been its Chief Executive Officer since March 16, 2018 and has been its President since March 7, 2016. M ...


CEO Compensation Analysis

Compensation vs. Market: Jerry has recently become CEO, making it difficult to compare their total compensation against companies of similar size in the US market.

Compensation vs Earnings: Jerry's compensation has been consistent with company performance over the past year.


Management Age and Tenure

1.0yrs

Average Tenure

52yo

Average Age

Experienced Management: MTNB's management team is not considered experienced ( 1 years average tenure), which suggests a new team.


Board Age and Tenure

3.4yrs

Average Tenure

54.5yo

Average Age

Experienced Board: MTNB's board of directors are considered experienced (3.4 years average tenure).


Insider Trading

Insider Buying: MTNB insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

BuyUS$13,20022 Aug 19
Eric Ende
EntityIndividual
Role
Member of the Board of Directors
Director
Shares20,000
Max PriceUS$0.66
BuyUS$9,97521 Aug 19
Jerome Jabbour
EntityIndividual
Role
Chief Executive Officer
Co-Founder
Shares14,650
Max PriceUS$0.68
BuyUS$13,65021 Aug 19
Eric Ende
EntityIndividual
Role
Member of the Board of Directors
Director
Shares20,000
Max PriceUS$0.68
BuyUS$7,26821 Aug 19
Adam Stern
EntityIndividual
Role
Member of the Board of Directors
Director
Shares10,400
Max PriceUS$0.70
BuyUS$71,85020 Aug 19
Patrick LePore
EntityIndividual
Role
Vice Chairman
Vice Chairman of the Board
Shares100,000
Max PriceUS$0.72
BuyUS$12,00018 Jun 19
A.K.S. Family Partners, L.P.
EntityCompany
Shares15,000
Max PriceUS$0.80
BuyUS$9,98013 Jun 19
Jerome Jabbour
EntityIndividual
Role
Chief Executive Officer
Co-Founder
Shares12,487
Max PriceUS$0.80
BuyUS$15,99813 Jun 19
A.K.S. Family Partners, L.P.
EntityCompany
Shares20,000
Max PriceUS$0.80
BuyUS$12,30011 Jun 19
A.K.S. Family Partners, L.P.
EntityCompany
Shares15,000
Max PriceUS$0.82
BuyUS$17,80010 Jun 19
A.K.S. Family Partners, L.P.
EntityCompany
Shares20,000
Max PriceUS$0.89
BuyUS$75,20003 Jun 19
A.K.S. Family Partners, L.P.
EntityCompany
Shares80,000
Max PriceUS$0.94
BuyUS$142,50020 May 19
A.K.S. Family Partners, L.P.
EntityCompany
Shares150,000
Max PriceUS$0.95
BuyUS$95,25020 May 19
Patrick LePore
EntityIndividual
Role
Vice Chairman
Vice Chairman of the Board
Shares100,000
Max PriceUS$0.95
BuyUS$24,11520 May 19
Herbert Conrad
EntityIndividual
Role
Chairman of the Board
Chairman of the Board
Shares25,000
Max PriceUS$0.96

Ownership Breakdown


Management Team

  • Raphael Mannino (72yo)

    Senior VP & Chief Scientific Officer

    • Tenure: 4.1yrs
    • Compensation: US$294.64k
  • Terry Ferguson (66yo)

    Chief Medical Officer

    • Tenure: 0.7yrs
  • Jerry Jabbour (45yo)

    Co-Founder

    • Tenure: 1.6yrs
    • Compensation: US$1.25m
  • Theresa Matkovits (52yo)

    Chief Development Officer

    • Tenure: 1yrs
  • Frank Calamusa

    Executive Director and Head of Manufacturing & Supply Chain

    • Tenure: 1yrs
  • Keith Kucinski (49yo)

    Chief Financial Officer

    • Tenure: 0.8yrs

Board Members

  • Pat LePore (64yo)

    Vice Chairman of the Board

    • Tenure: 1.1yrs
    • Compensation: US$159.45k
  • Herb Conrad (86yo)

    Chairman of the Board

    • Tenure: 6.3yrs
    • Compensation: US$256.00k
  • Adam Stern (55yo)

    Director

    • Tenure: 6.3yrs
    • Compensation: US$210.00k
  • Jim Scibetta (54yo)

    Director

    • Tenure: 5.9yrs
    • Compensation: US$235.00k
  • David Perlin

    Member of Scientific Advisory Board

    • Tenure: 4.3yrs
  • Christie Ballantyne

    Member of Scientific Advisory Board

    • Tenure: 0.8yrs
  • Eric Ende (50yo)

    Director

    • Tenure: 2.5yrs
    • Compensation: US$231.50k
  • J. Craft

    Member of Scientific Advisory Board

    • Tenure: 0yrs
  • Peter Pappas

    Member of Scientific Advisory Board

    • Tenure: 0yrs
  • Jerry Jabbour (45yo)

    Co-Founder

    • Tenure: 1.6yrs
    • Compensation: US$1.25m

Company Information

Matinas BioPharma Holdings, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Matinas BioPharma Holdings, Inc.
  • Ticker: MTNB
  • Exchange: AMEX
  • Founded: 2013
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$113.244m
  • Shares outstanding: 162.43m
  • Website: https://www.matinasbiopharma.com

Number of Employees


Location

  • Matinas BioPharma Holdings, Inc.
  • 1545 Route 206 South
  • Suite 302
  • Bedminster
  • New Jersey
  • 7921
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
MTNBAMEX (NYSE MKT LLC)YesCommon StockUSUSDJun 2014
6LJDB (Deutsche Boerse AG)YesCommon StockDEEURJun 2014

Biography

Matinas BioPharma Holdings, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of various product candidates. The company develops products using its lipid nano-crys ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/10/21 00:34
End of Day Share Price2019/10/18 00:00
Earnings2019/06/30
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.